Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.49 |
| ▸ | CNR1 | P21554 | 6/20 | 0.45 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | CCNC | P24863 | 1/20 | 0.42 |
| ▸ | CDK8 | P49336 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 4/20 | 0.41 |
| ▸ | CDC7 | O00311 | 3/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.41 |
| ▸ | DBF4 | Q9UBU7 | 3/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24750230 | 0.94 | PTGS2 (0.46) | PTGS2CNR1EGFRCDK2CDC7 | |
| SCHEMBL21801500 | 0.91 | CDC7 (0.50) | PTGS2CNR1EGFRCDK2CDC7 | |
| SCHEMBL21801557 | 0.89 | CNR1 (0.52) | PTGS2CNR1EGFRCDK2 | |
| SCHEMBL21801499 | 0.83 | BCL2 (0.50) | NPC1RAB9A | |
| SCHEMBL21801498 | 0.81 | GSK3B (0.46) | PTGS2CNR1EGFRNPC1RAB9A | |
| SCHEMBL21801479 | 0.79 | QPCT (0.48) | PTGS2CNR1EGFRNPC1RAB9A | |
| SCHEMBL21801474 | 0.79 | NPC1 (0.46) | EGFRCCNCCDK8CDK2CDC7 | |
| SCHEMBL21801526 | 0.78 | CDC7 (0.48) | CNR1CDK2CDC7CCNE1DBF4 | |
| SCHEMBL21801525 | 0.78 | MAPT (0.53) | EGFRNPC1RAB9A | |
| SCHEMBL21801489 | 0.77 | PRNP (0.40) | CNR1EGFRCCNCCDK8CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220257569-A1 | INDOLE-OXADIAZOLE COMPOUNDS AND THEIR THERAPEUTIC USE | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2022-08-18 | — | — | US | disclosed |
| WO-2020051707-A1 | INDOLE-OXADIAZOLE COMPOUNDS AND THEIR THERAPEUTIC USE | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2020-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220257569-A1 | INDOLE-OXADIAZOLE COMPOUNDS AND THEIR THERAPEUTIC USE | CNR2, GPR119, CNR1 | PTGS2 1785/4885CNR1 3/4885EGFR 2634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.